Renal Artery Denervation for Treating Resistant Hypertension
- 29 December 2012
- journal article
- practice guideline
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 19 (4) , 237-244
Abstract
Arterial hypertension is responsible for a significant burden of cardiovascular morbidity and mortality, worldwide. Although several rational and integrated pharmacological strategies are available, the control of high blood pressure still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on individual global cardiovascular risk, since it significantly increases the risk of developing hypertension-related macrovascular and microvascular complications. Arterial hypertension is arbitrarily defined as ‘resistant’ or ‘refractory’ when the recommended blood pressure goals (clinic blood pressure below 140/90 mmHg or below 130/80 mmHg in patients with type 2 diabetes mellitus or nephropathy) are not achieved in the presence of a therapeutic strategy that includes lifestyle changes and at least three classes of antihypertensive drugs, including a diuretic, at adequate doses. Recently, an innovative non-pharmacological option has become available for treating resistant hypertension. Sympathetic denervation of renal arteries is a minimally invasive procedure that is performed via percutaneous access from the femoral artery. It consists of radiofrequency ablation of the afferent and efferent nerves of the renal sympathetic nervous system, with consequent isolation of renal parenchymal and juxtaglomerular structures from abnormal stimulation of the efferent adrenergic system. The present position paper of the Italian Society of Hypertension (SIIA) offers a diagnostic and therapeutic approach for the proper identification and effective clinical management of patients with resistant hypertension, who are candidates for renal artery denervation. These indications may have important implications not only from a clinical point of view, but also from an economic point of view, since a proper identification of patients with true resistant hypertension and an accurate selection of patients suitable for the procedure of renal denervation can contribute to an improved control of blood pressure, and thus a reduced risk of cardiovascular and cerebrovascular complications in these patients.Keywords
This publication has 25 references indexed in Scilit:
- Blood pressure control and knowledge of target blood pressure in coronary patients across EuropeJournal Of Hypertension, 2011
- Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA studyEuropean Journal of Preventive Cardiology, 2011
- A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive PatientsThe Journal of Clinical Hypertension, 2010
- Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertensionJournal Of Hypertension, 2009
- Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trialsBMJ, 2008
- Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deathsThe Lancet, 2007
- Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes MellitusArchives of internal medicine (1960), 2005
- Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsThe Lancet, 2003
- Essential hypertensionThe Lancet, 2003
- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 2002